Link to the full source article

RSS feed source: Centers for Disease Control and Prevention--Office of Public Health Preparedness and Response

Today, CDC announced the release of more than 77,000 additional doses of Beyfortus(TM) (nirsevimab-alip (100 mg), a long-acting monoclonal antibody designed to protect infants against severe respiratory syncytial virus (RSV) disease. 

Click this link to continue reading the article on the source website.